Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity

Advanced Drug Delivery Reviews

Volumn 91, Issue , 2015, Pages 3-6

  Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Anticancer drugs; EPR effect artifacts; EPR effect dependence on time and molecular size; EPR effect dynamics; Macromolecular drugs; Nanomedicines

Indexed keywords

BLOOD; BLOOD PRESSURE; DRUG DELIVERY; DRUG PRODUCTS; MACROMOLECULES; MEDICAL NANOTECHNOLOGY;

ANTICANCER DRUG; ENHANCED PERMEABILITY AND RETENTION EFFECTS; EPR EFFECT; HYDRODYNAMIC FORCES; MACROMOLECULAR DRUGS; MOLECULAR SIZE; PHYSIOLOGICAL CHARACTERISTICS; SYSTOLIC BLOOD PRESSURE;

TUMORS;

DOXORUBICIN; GEMCITABINE; IODINATED POPPYSEED OIL; LIPOSOME; PACLITAXEL; PIRARUBICIN; ANTINEOPLASTIC AGENT; MACROMOLECULE; MICELLE;

ANTINEOPLASTIC ACTIVITY; ARTIFACT; BIOCOMPATIBILITY; BLOOD PRESSURE; BONE METASTASIS; CARCINOGENESIS; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; ENHANCED PERMEABILITY AND RETENTION; HEAT; HETEROGENEITY; HUMAN; HYDROPHOBICITY; HYPERTENSION; INFLAMMATORY CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MACROMOLECULE; METASTASIS; MICELLE; MOLECULAR SIZE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STATISTICS; SURFACE CHARGE; TIME; ADMINISTRATION AND DOSAGE; ANIMAL; NEOPLASMS; PATHOLOGY; PERMEABILITY; PHARMACOKINETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; LIPOSOMES; MACROMOLECULAR SUBSTANCES; MICELLES; NANOMEDICINE; NEOPLASMS; PERMEABILITY;

EID: 84940956193     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.01.002     Document Type: Review

References (38)

1. Lammers T. Editorial: Drug delivery research in Europe. J. Control. Release 2012, 161:151.
2. Brambilla D., Luciani P., Leroux J.C. Breakthrough discoveries in drug delivery technologies: the next 30years. J. Control. Release 2014, 190:9-14.
3. Taurin S., Nehoff H., Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link?. J. Control. Release 2012, 164:265-275.
4. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improved tumor uptake, less systemic toxicity, and improved tumor imaging-review of the vascular permeability of tumors and the EPR effect. Adv. Drug Deliv. Rev. 2013, 65:71-79.
5. Fang J., Nakamura H., Maeda H. EPR effect: the unique characteristics of tumor blood vessels for drug delivery, factors involved, its limitation and augmentation. Adv. Drug Deliv. Rev. 2011, 63:136-151.
6. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
7. Maeda H. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 2013, 104:779-789.
8. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89:307-314.
9. Maeda H., Matsumoto T., Konno T., Iwai K., Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on smancs. J. Protein Chem. 1984, 3:181-193.
10. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., Miyauchi Y. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984, 54:2367-2374.
11. Maki S., Konno T., Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985, 56:751-757.
12. Iwai K., Maeda H., Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 1984, 44:2115-2121.
13. Nagamitsu A., Greish K., Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 2009, 39:756-766.
14. Maeda H. Enhanced permeability and retention effect in relation to tumor targeting. From Basic Research to Cancer Therapy 2011, vol. 1:65-84. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. F. Kratz, P. Senter, H. Steinhagen (Eds.).
15. Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc. Jpn. Acad. Ser. B 2012, 88:53-71.
16. Barbosa M. What is the best treatment for a cancer patient with thrombosis?. Clin. Med. Insights Oncol. 2014, 8:49-55.
17. Seki T., Fang J., Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 2009, 100:2426-2430.
18. Maeda H. Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J. Control. Release 2010, 142:296-298.
19. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 2012, 164:138-144.
20. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E., Zamboni W., Farokhzad O.C., Barry S.T., Gabizon A., Grodzinski P., Blakey D.C. Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res. 2013, 73:2412-2417.
21. Nakamura H., Fang J., Maeda H. Development for next generation drugs based on the EPR effect: challenges and pitfalls. Expert Opin. Drug Deliv. 2015, 12:53-64.
22. Maeda H., Takeshita J., Kanamaru R. A lipophilic derivative of neocarzinostatin: a polymer conjugation of an antitumor protein antibiotic. Int. J. Peptide Protein Res. 1979, 14:81-87.
23. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6:193-210.
24. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 1991, 6:181-202.
25. Maeda H., Takeshita J., Yamashita A. Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur. J. Cancer 1980, 16:723-731.
26. Tsukigawa K., Liao L., Nakamura H., Fang J., Greish K., Otagiri M., Maeda H. Synthesis and therapeutic effect of styrene-maleic acid copolymer conjugated pirarubicin. Cancer Sci. 2015, (in press).
27. Daruwalla J., Nikfarjam M., Greish K., Malcontenti-WilsonI C., Muralidharan V., Christophi C., Maeda H. In vitro and in vivo evaluation of tumor targeting SMA-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci. 2010, 101:1866-1874.
28. Dozono H., Yanazume S., Nakamura H., Etrych T., Chytil P., Ulbrich K., Fang J., Arimura T., Douchi T., Kobayashi H., Ikoma M., Maeda H. Multimodal therapy of a stage IV prostate cancer patient with extensive lung and bone metastases with HPMA polymer conjugated pirarubicin given intravenously 2015, (unpublished data).
29. Nakamura H., Etrych T., Chytil P., Ohkubo M., Fang J., Ulbrich K., Maeda H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release 2014, 174:81-87.
30. Park K. Questions on the role of the EPR effect in tumor targeting. J. Control. Release 2013, 172:391.
31. Hollis C.P., Weiss H.L., Leggas M., Evers B.M., Gemeinhart R.A., Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J. Control. Release 2013, 172:12-21.
32. Nichols J.W., Bae Y.H. EPR: evidence and fallacy. J. Control. Release 2014, 190:451-464.
33. Kratz F., Beyer U., Schumacher P., Krüger M., Zahn H., Roth T., Fiebig H.H., Unger C. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates. Bioorg. Med. Chem. Lett. 1997, 7:617-622.
34. Li C.J., Miyamoto Y., Kojima Y., Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 1993, 67:975-980.
35. Chytil P., Hoffmann S., Schindler L., Kostka L., Ulbrich K., Caysa H., Mueller T., Mäder K., Etrych T. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. J. Control. Release 2013, 172:504-512.
36. Etrych T., Jelínková M., Říhová B., Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 2001, 73:89-102.
37. Oda T., Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res. 1987, 47:3206-3211.
38. Zhanga R., Yanga J., Simaa M., Zhoua Y., Kopecek J. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc. Natl. Acad. Sci. 2014, 111:12181-12186.